Goblet cell hyperplasia

Goblet cell hyperplasia (GCH) is a pathological condition characterized by an abnormal increase in the number of mucus-secreting goblet cells within the epithelial lining, primarily in the respiratory and gastrointestinal tracts. It is a defining feature of chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), where it leads to excessive mucus production, airway plugging, and decreased lung function (StatPearls, NBK559281). The process is largely driven by inflammatory stimuli, particularly the Th2 cytokine interleukin-13 (IL-13), which activates the STAT6 signaling pathway to induce the expression of the master regulator transcription factor SPDEF (PubMed, 12154377). While GCH is not a single molecular target or receptor, it serves as a critical histological endpoint for drug development and therapeutic evaluation. Treatment strategies focused on GCH typically involve biologics that neutralize upstream cytokines, such as Dupilumab (targeting IL-4Rα) or Tralokinumab (targeting IL-13), which effectively reduce goblet cell numbers and mucin expression (NCI Thesaurus, C3058). For biotech analysts, GCH represents a major therapeutic challenge because its resolution is essential for long-term improvement in airway clearance and symptom control in obstructive lung diseases.

Other names

Goblet cell metaplasiaMucous cell hyperplasiaMucous metaplasiaMucous gland hyperplasia

Current therapeutic strategies do not target the hyperplasia itself as a molecule, but rather inhibit the upstream signaling pathways (e.g., IL-4Rα/IL-13 axis, EGFR signaling) or transcription factors (e.g., SPDEF) that drive the differentiation of basal or ciliated cells into mucus-producing goblet cells.